Aveo Capital Partners’s Biogen BIIB Stock Holding History

Aveo Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,175	Closed	-$329K	–	264
2021 Q1	$329K	Buy	+1,175	New	+$317K	0.08%	179

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Aveo Capital Partners's BIIB Position: Q2 2021 in Review

Aveo Capital Partners sold out of Biogen (BIIB) in Q2 2021, closing a stake of 1,175 shares — an estimated $329K sold.

Aveo Capital Partners first reported a position in BIIB in Q1 2021 and held it in 1 quarter. The position peaked at $329K in Q1 2021. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Aveo Capital Partners reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Aveo Capital Partners sold 1,175 Biogen shares in Q2 2021, an estimated $329K.
Aveo Capital Partners first reported a position in Biogen in Q1 2021 and held it in 1 quarter.
Aveo Capital Partners's Biogen position peaked at $329K in Q1 2021.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Aveo Capital Partners's 13F filing for Q2 2021, filed 13 Aug 2021.